News

Legend Biotech Reveals Significant Updates in Cancer Treatment

Legend Biotech Reveals Significant Updates in Cancer Treatment

Exciting Advancements by Legend Biotech in Cancer Treatments

On May 22, 2025, Legend Biotech Corporation (NASDAQ: LEGN) announced significant findings related to CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), a revolutionary therapy for multiple myeloma. This news comes as the company prepares to unveil breakthrough data at prominent oncology events, including the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association’s (EHA) Congress.

Highlights from the CARTITUDE Studies

At ASCO and EHA, Legend Biotech will present compelling data from the CARTITUDE-1 study, focusing on patients who have undergone heavy treatment yet enjoyed long-term remission, some exceeding five years post a single CARVYKTI® infusion. This oral presentation aims to highlight CARVYKTI®’s potential as a frontrunner in the CAR-T sector for multiple myeloma, particularly for patients historically expected to have a median progression-free survival of under six months.

Impressive Progression-Free Rates

Additionally, the CARTITUDE-4 study will showcase improved progression-free survival rates among patients receiving CARVYKTI® when compared to standard treatments. This data will be impactful, particularly for patients identified with high-risk cytogenetic features, as it underscores CARVYKTI®’s positive benefit-risk assessment across various patient demographics.

Emerging Research in Solid Tumors

Further illustrating Legend Biotech's vast reach within oncology is the presentation of preliminary results from two ongoing Phase 1 dose-escalation trials featuring LB2102 and LB1908. These trials, exploring new therapies for lung and gastroesophageal cancers, respectively, indicate that Legend is keen on expanding its cell therapy applications beyond hematological cancers.

Insights on New Therapies

These ongoing studies will be featured at ASCO, providing insights into these novel therapies that aim to address significant unmet medical needs in treating solid tumors. Furthermore, data on LB2102 has been previously presented at the ASGCT Annual Meeting, keeping the medical and scientific communities engaged and informed of progress.

Strengthening Partnerships for Future Innovations

In a strategic move, Legend Biotech recently entered into a global licensing agreement with Novartis, enhancing their reach and capabilities in the field of CAR-T therapies targeting DLL3. This collaboration is expected to streamline the Phase 1 clinical trials of LB2102 in the U.S., with Novartis managing all additional product development.

Details of Planned Presentations

During the upcoming ASCO and EHA presentations, significant abstracts will be discussed, including the following:
1. **Abstract #7507**: Long-term outcomes from the CARTITUDE-1 study, focusing on patients with relapsed/refractory multiple myeloma.
2. **Abstract #7539**: Comparative analysis of CARVYKTI® against standard care in multiple myeloma patient subgroups.
3. **Abstract #4022**: Early results relating to LB1908’s effectiveness in advanced gastroesophageal adenocarcinoma.
4. **Abstract #8104**: Evaluation of LB2102 in relapsed or refractory small cell lung cancer (SCLC).

Safety Profiles and Future Directions

As part of their commitment to transparency, Legend Biotech will also address important safety information regarding CARVYKTI®, stressing the necessity for patient monitoring due to potential adverse effects like cytokine release syndrome (CRS) and neurologic toxicities. This proactive approach will ensure that healthcare professionals are well-informed about the risks associated with CARVYKTI® treatment and can better manage patient care.

Legend Biotech remains dedicated to transforming the landscape of oncology through innovative therapies. As they move forward, the company is set to foster further advancements, ensuring patients receive efficient and potentially life-saving treatments.

Frequently Asked Questions

What is CARVYKTI®?

CARVYKTI® (ciltacabtagene autoleucel) is an FDA-approved CAR-T therapy designed for patients with relapsed or refractory multiple myeloma. It utilizes genetically modified T-cells to target and eliminate tumor cells.

How does Legend Biotech contribute to cancer treatment innovation?

Legend Biotech invests heavily in research and development, collaborating with partners like Novartis to expand its range of treatments, focusing on both hematological and solid tumors.

What studies will Legend Biotech present at upcoming conferences?

Legend Biotech will share data from the CARTITUDE-1 and CARTITUDE-4 studies concerning CARVYKTI®, alongside preliminary findings from trials involving LB2102 and LB1908.

What safety concerns are associated with CARVYKTI®?

Safety risks include cytokine release syndrome (CRS) and neurologic toxicities. Patients must be closely monitored for these effects during and after treatment.

How can patients access CARVYKTI®?

CARVYKTI® is available exclusively through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) to manage the associated risks effectively.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

TNBC Advocate Campaign Targets Gaps in Patient Clarity

Updated Category News Views 103

Triple-negative is a heavy phrase to hand somebody without a map. Tigerlily Foundation and the Breast Cancer Resource Center are trying to close that gap with a national education campaign scheduled to launch publicly on January 11, 2027. The plan is straightforward on paper: train and mobilize 100 patient advocates across the country to explain triple-negative breast...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 113

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 20

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 82

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 16

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 51

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
Bill Targets 15% Federal Goal for Women-Owned Firms

Updated Category News Views 56

Federal procurement has a stubborn habit of sounding abstract until you remember that contracts can decide whether a small company hires, invests, or simply keeps the lights on. Senator Adam Schiff introduced the Women's Economic Fairness and Small Business Contracting Act on November 19, 2026, proposing to raise the federal goal for Women-Owned Small Businesses from 5%...

Continue Reading
Green Lumber Recall Raises a Serious Safety Question

Updated Category News Views 46

A blister-pack code is doing far more work than it ever should. Green Lumber Holdings is recalling Green Lumber Natural Fuel For Men, lot GL01 with expiration 09/27, after FDA laboratory analysis confirmed undeclared tadalafil in additional samples. The company says the consumer-level recall begins November 19, 2026. This is not a cute labeling nitpick or a marketing...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 63

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 91

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading

Top 5 Most Recently Viewed Articles

Pharvaris Shares Promising Data on Deucrictibant Efficacy

Updated Category News Views 186

Pharvaris Highlights Clinical Progress in HAE Treatment At the recent AAAAI/WAO Joint Congress, Pharvaris presented compelling long-term clinical data supporting the use of deucrictibant, a novel oral treatment for hereditary angioedema (HAE). This data underscores the drug's potential to not only prevent but also effectively address HAE attacks, offering hope to those...

Continue Reading
First Horizon Opens New Banking Center Celebrating Local Pride

Updated Category News Views 349

First Horizon Unveils New Banking Center with Appalachian Spirit First Horizon Bank (NYSE: FHN) proudly celebrated the grand opening of its newly refreshed banking center. The location pays tribute to the vibrant Appalachian State community, showcasing a striking theme that reflects its strong ties with Appalachian State University and its athletics. This celebration...

Continue Reading
Understanding Namodenoson's Role in Liver Cancer and Beyond

Updated Category News Views 243

Innovative Research on Namodenoson’s Impact in Liver Cancer Therapy Namodenoson, developed by Can-Fite BioPharma Ltd., is making waves in the medical community as a promising candidate for liver cancer treatment. Unlike traditional chemotherapy, which often harms healthy cells, Namodenoson is lauded for its protective qualities towards normal body systems. Published...

Continue Reading
Geotab Enhances Public Sector Solutions with Technological Advancements

Updated Category News Views 147

Geotab Enhances Public Sector Solutions with Technological Advancements Geotab Inc., a leader in connected vehicle solutions and asset management, has taken a major step forward in serving the public sector by expanding its cooperative purchasing contracts with Sourcewell and Canoe Procurement Group. This expansion introduces four cutting-edge solutions aimed at enhancing...

Continue Reading
Dun & Bradstreet Earns TRUSTe Certification for Responsible AI

Updated Category News Views 351

Dun & Bradstreet Achieves TRUSTe Responsible AI Certification Dun & Bradstreet (NYSE:DNB), recognized globally as a leading provider of business decisioning data and analytics, has been awarded the TRUSTe Responsible AI Certification. This certification signifies the company’s commitment to ethical and responsible governance in the realm of artificial intelligence (AI)....

Continue Reading